Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Interventions for chronic kidney disease in people with sickle cell disease
source: Cochrane Database of Systematic Reviews
year: 2017
authors: Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ
summary/abstract:BACKGROUND:
Sickle cell disease (SCD) is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta-globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD.Chronic kidney disease is defined as abnormalities of kidney structure or function, present for more than three months. Sickle cell nephropathy refers to the spectrum of kidney complications in SCD.Glomerular damage is a cause of microalbuminuria and can develop at an early age in children with SCD, and increases in prevalence in adulthood. In people with sickle cell nephropathy, outcomes are poor as a result of the progression to proteinuria and chronic kidney insufficiency. Up to 12% of people who develop sickle cell nephropathy will develop end-stage renal disease.
OBJECTIVES:
To assess the effectiveness of any intervention in preventing or reducing kidney complications or chronic kidney disease in people with SCD (including red blood cell transfusions, hydroxyurea and angiotensin-converting enzyme inhibitor (ACEI)), either alone or in combination with each other.
AUTHORS’ CONCLUSIONS:
In young children aged 9 months to 18 months, we are very uncertain if hydroxyurea improves glomerular filtration rate or reduces hyperfiltration, but it may improve young children’s ability to concentrate urine and may make little or no difference on the incidence of acute chest syndrome, painful crises and hospitalisations. We are very uncertain if giving ACEI to adults with normal blood pressure and microalbuminuria has any effect on preventing or reducing kidney complications.This review identified no trials that looked at red cell transfusions nor any combinations of interventions to prevent or reduce kidney complications. Due to lack of evidence this review cannot comment on the management of either children aged over 18 months or adults with any known genotype of SCD.We have identified a lack of adequately-designed and powered studies, and no ongoing trials which address this critical question. Trials of hydroxyurea, ACEI or red blood cell transfusion in older children and adults are urgently needed to determine any effect on prevention or reduction kidney complications in people with SCD.
DOI: 10.1002/14651858.CD012380.pub2
read more full text
Related Content
-
Sickle Cell Disease: Managing PainCurrently, sickle cell disease has no wi...
-
Mona Robbins, PhDDr. Mona Robbins is an Associate Profess...
-
University of Maryland Medical CenterThe University of Maryland Medical Cente...
-
Acute Vaso-Occlusive pain associated with the onset of menstruation is distinct from dysmenorrhea in sickle cell dis...Acute vaso-occlusive pain episodes are t...
-
A Career Inspired by DiseaseMs. Dobson says that her worst symptom i...
-
Timothy Lee McCavit, MDTimothy L. McCavit earned a MS in molecu...
-
Darryl Watkins Stays Positive in Spite of Sickle Cell DiseaseDarryl Watkins has the HbSS variant of s...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
+myBinder